Format

Send to

Choose Destination
Clin Exp Immunol. 2013 May;172(2):148-57. doi: 10.1111/cei.12038.

Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?

Author information

1
Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. catharien.hilkens@ncl.ac.uk

Abstract

Dendritic cells with tolerogenic function (tolDC) have become a promising immunotherapeutic tool for reinstating immune tolerance in rheumatoid arthritis (RA) and other autoimmune diseases. The concept underpinning tolDC therapy is that it specifically targets the pathogenic autoimmune response while leaving protective immunity intact. Findings from human in-vitro and mouse in-vivo studies have been translated into the development of clinical grade tolDC for the treatment of autoimmune disorders. Recently, two tolDC trials in RA and type I diabetes have been carried out and other trials are in progress or are imminent. In this review, we provide an update on tolDC therapy, in particular in relation to the treatment of RA, and discuss the challenges and the future perspectives of this new experimental immunotherapy.

PMID:
23574312
PMCID:
PMC3628318
DOI:
10.1111/cei.12038
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center